We’re proud to have brokered a major deal for our German precision medicine technology client Molecular Health – to enable South Korea’s Konyang University Hospital to transform its cancer care.
The deal is an early result from the business development programmes we’re running for Molecular Health in South Korea, Japan and Taiwan.
Based in Heidelberg, Molecular Health is a biomedical IT company which has developed innovative, AI-based precision medicine software called MH Guide. This helps molecular pathologists and oncologists to interpret next generation sequencing data and make tailored care decisions.
Konyang University Hospital – operating under the motto ‘World class quality with love' – is the first Korean hospital to license MH Guide to enable it to deliver personalised treatment. Its Cancer Centre Director, Yoon Dae-seong, explained: “With our next generation sequencing system and MH Guide, we now have a complete precision medicine ecosystem that will enable us to provide world-class cancer care."
Konyang University Hospital team using MH Guide to create cancer treatment plan
The landmark deal is the result of the long-term programme our medtech team in Seoul is delivering for Molecular Health, which includes:
- researching Korea’s precision oncology market and clarifying relevant data transfer and privacy regulations
- engaging Korean key opinion leaders, cancer centre and lab directors, medical associations and regulators
- running seminars for hospitals and physicians, and
- nurturing a pipeline of priority prospective customers
Stephan Hettich, Molecular Health’s Head of APAC Business Development, said:
"Winning a big contract with an Asian hospital is no easy task at the best of times. And because of the depth of stakeholder liaison and relationship building needed, it would have been impossible for us to have achieved remotely during the pandemic.
"That’s where Intralink’s teams on the ground in Seoul, Tokyo and Taipei are proving invaluable. They’re knowledgeable, well-connected and highly responsive – and this contract is a fantastic first result from all their persistence and hard work.
This is just the beginning of the process for us: they’ve got some other significant potential deals in the works and we’re making great inroads into these challenging but important East Asian markets."
To discuss the opportunities for your medtech business in East Asia, contact Graham Barker at firstname.lastname@example.org